The field of peptides is exploding, Perpetual Medicines Corp. co-founder, chairman and CEO Kerry L. Blanchard recently told BioWorld, “with a projected growth rate far surpassing large and small molecules, and gene therapies. The area is underinvested, too, so this is a good opportunity to focus on peptide therapeutics.”

The field of peptides is exploding, Perpetual Medicines Corp. co-founder, chairman and CEO Kerry L. Blanchard recently told BioWorld, “with a projected growth rate far surpassing large and small molecules, and gene therapies. The area is underinvested, too, so this is a good opportunity to focus on peptide therapeutics.”

The field of peptides is exploding, Perpetual Medicines Corp. co-founder, chairman and CEO Kerry L. Blanchard recently told BioWorld, “with a projected growth rate far surpassing large and small molecules, and gene therapies. The area is underinvested, too, so this is a good opportunity to focus on peptide therapeutics.” Blanchard, who was most recently CEO of Shanghai-based Everest Medicines Ltd. and previous chief scientific officer (CSO) of China’s Innovent Biologics Co. Ltd., is now spearheading efforts to develop novel peptide therapeutics at his own biotech, Perpetual, founded in March 2023.

Qnovia Inc. has entered into a drug development collaboration with the University of Virginia (UVA) to advance novel inhaled drug candidates.

Silo Pharma Inc. has announced promising data from a preclinical study investigating the binding affinity and optimization of SPU-21 liposomal joint homing peptide in human synovial tissue surrounding joints and tendons.

Peptidream Inc. has entered into a new multitarget collaboration and license agreement with Genentech, a member of the Roche Group, focused on the discovery and development of novel macrocyclic peptide-radioisotope drug conjugates.

Evergreen Discovery (Evergreen Theragnostics Inc.) and Orbit Discovery Ltd. have entered into a collaboration to identify specific cell-targeting peptides and advance the development of novel radiopharmaceuticals.

Rayzebio Inc. has nominated a first-in-class novel peptide drug candidate against glypican-3...

Silo Pharma Inc. plans to initiate a pilot study of SPU-21, its novel joint-homing peptide targeting rheumatoid arthritis (RA), in human synovial tissue surrounding joints and tendons.

Vivasc Therapeutics Inc. has initiated work under a second National Institutes of Health (NIH) phase I STTR research grant, in conjunction with Georgetown University.